Halozyme Therapeutics Management

Management criteria checks 2/4

Halozyme Therapeutics' CEO is Helen Torley, appointed in Jan 2014, has a tenure of 10.33 years. total yearly compensation is $11.82M, comprised of 7.8% salary and 92.2% bonuses, including company stock and options. directly owns 0.53% of the company’s shares, worth $25.78M. The average tenure of the management team and the board of directors is 2.3 years and 10.3 years respectively.

Key information

Helen Torley

Chief executive officer

US$11.8m

Total compensation

CEO salary percentage	7.8%
CEO tenure	10.3yrs
CEO ownership	0.5%
Management average tenure	2.3yrs
Board average tenure	10.3yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Helen Torley's remuneration changed compared to Halozyme Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	US$12m	US$920k	US$282m
Sep 30 2023	n/a	n/a	US$254m
Jun 30 2023	n/a	n/a	US$234m
Mar 31 2023	n/a	n/a	US$182m
Dec 31 2022	US$10m	US$872k	US$202m
Sep 30 2022	n/a	n/a	US$211m
Jun 30 2022	n/a	n/a	US$366m
Mar 31 2022	n/a	n/a	US$435m
Dec 31 2021	US$7m	US$830k	US$403m
Sep 30 2021	n/a	n/a	US$409m
Jun 30 2021	n/a	n/a	US$229m
Mar 31 2021	n/a	n/a	US$163m
Dec 31 2020	US$7m	US$791k	US$129m
Sep 30 2020	n/a	n/a	US$22m
Jun 30 2020	n/a	n/a	-US$40m
Mar 31 2020	n/a	n/a	-US$80m
Dec 31 2019	US$6m	US$761k	-US$72m
Sep 30 2019	n/a	n/a	-US$40m
Jun 30 2019	n/a	n/a	-US$43m
Mar 31 2019	n/a	n/a	-US$51m
Dec 31 2018	US$6m	US$725k	-US$80m
Sep 30 2018	n/a	n/a	US$46m
Jun 30 2018	n/a	n/a	US$76m
Mar 31 2018	n/a	n/a	US$68m
Dec 31 2017	US$5m	US$671k	US$63m

Compensation vs Market: Helen's total compensation ($USD11.82M) is above average for companies of similar size in the UK market ($USD3.32M).

Compensation vs Earnings: Helen's compensation has increased by more than 20% in the past year.

CEO

Helen Torley (60 yo)

10.3yrs

Tenure

US$11,820,858

Compensation

Dr. Helen I. Torley, M.B. Ch. B., M.R.C.P. has been Chief Executive Officer and President of Halozyme Therapeutics, Inc. since January 6, 2014. Prior to joining Halozyme in January 2014, she served as the...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Helen Torley	President	10.3yrs	US$11.82m	0.53% $ 25.8m
Nicole LaBrosse	Senior VP & CFO	2.3yrs	US$3.85m	0.012% $ 589.6k
Michael LaBarre	Senior VP & CTO	no data	US$3.24m	0.13% $ 6.4m
Mark Snyder	Senior VP & Chief Legal Officer	2.3yrs	US$3.61m	0.0092% $ 444.9k
Cortney Caudill	Chief Operations Officer	less than a year	no data	no data
Tram Bui	Head of Investor Relations & Corporate Communications	2.3yrs	no data	no data
Amy Fox	Senior Vice President of Human Resources	4.3yrs	no data	no data
Kristin Schwartzbauer	Head of Quality	no data	no data	no data
Gary Grote	Chief Commercial Officer	less than a year	no data	no data
Christopher Wahl	Chief Business Officer	less than a year	no data	no data

2.3yrs

Average Tenure

59yo

Average Age

Experienced Management: 0J2O's management team is considered experienced (2.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Helen Torley	President	10.3yrs	US$11.82m	0.53% $ 25.8m
Connie Matsui	Independent Director	17.8yrs	US$460.02k	0.15% $ 7.1m
Jeffrey Henderson	Independent Chair of the Board	8.8yrs	US$555.02k	0.037% $ 1.8m
Daniel Von Hoff	Member of the Scientific Advisory Board	19.8yrs	no data	no data
Barbara Duncan	Independent Director	1.3yrs	US$528.15k	no data
Jeffrey Bleil	Member of the Advisory Board	no data	no data	no data
Gregory Frost	Chairman of Scientific Advisory Board	10.3yrs	US$68.17k	no data
Gerhard Baumgartner	Member of Scientific Advisory Board	19.9yrs	no data	no data
Sue Bailey	Member of Scientific Advisory Board	18.8yrs	no data	no data
Matthew Posard	Independent Director	11.2yrs	US$471.83k	0.083% $ 4.0m
Bernadette Connaughton	Independent Director	5.7yrs	US$470.02k	0.032% $ 1.5m
Moni Miyashita	Independent Director	2.2yrs	US$455.02k	0.0049% $ 236.2k

10.3yrs

Average Tenure

65yo

Average Age

Experienced Board: 0J2O's board of directors are seasoned and experienced ( 10.3 years average tenure).

Halozyme Therapeutics Management

Management criteria checks 2/4

Key information

Recent management updates

Halozyme Therapeutics, Inc. Announces the Election of Mahesh Krishnan, M.D. to its Board of Directors

Halozyme Therapeutics, Inc., Annual General Meeting, Apr 25, 2024

Independent Director recently sold US$875k worth of stock

Insufficient new directors

Insufficient new directors

Independent Director recently sold US$962k worth of stock

Recent updates

Halozyme Therapeutics, Inc. Announces the Election of Mahesh Krishnan, M.D. to its Board of Directors

Halozyme Therapeutics, Inc. to Report Q1, 2024 Results on May 07, 2024

Halozyme Therapeutics, Inc., Annual General Meeting, Apr 25, 2024

Full year 2023 earnings released: EPS: US$2.13 (vs US$1.48 in FY 2022)

Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Year 2024

Halozyme Therapeutics, Inc. to Report Q4, 2023 Results on Feb 20, 2024

Halozyme Announces Argenx Receives Approval in Japan for Vyvdura®? Co-Formulated with Enhanze®? for Generalized Myasthenia Gravis

Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Twelve Months Ended December 31, 2023

Halozyme Announces Takeda Receives FDA Approval for Hyqvia® Co-Formulated with Enhanze® as Maintenance Therapy in Adults with Chronic Inflammatory Demyelinating Polyneuropathy

Halozyme Announces Roche Receives European Commission Approval of Tecentriq®? SC with ENHANZE®? Representing the EU's First Subcutaneous PD(L)1 Cancer Immunotherapy for Multiple Cancer Types

Third quarter 2023 earnings released: EPS: US$0.62 (vs US$0.45 in 3Q 2022)

Halozyme Therapeutics, Inc. to Report Q3, 2023 Results on Nov 06, 2023

Halozyme Therapeutics, Inc. Reports Positive Topline Results from the Phase 3 Checkmate-67T Trial Evaluating Subcutaneous (SC) Formulation of Opdivo (Nivolumab) with Enhanze

Halozyme Announces Positive Clinical Data of its High-Volume Auto-Injector Demonstrating Successful Rapid Subcutaneous Drug Delivery

Halozyme Therapeutics, Inc Announces Approval of Roche's Tecentriq® Subcutaneous (SC) with ENHANZE® in Great Britain

Independent Director recently sold US$875k worth of stock

Second quarter 2023 earnings released: EPS: US$0.57 (vs US$0.16 in 2Q 2022)

Halozyme Therapeutics, Inc. Revises Earnings Guidance for the Full Year 2023

Halozyme Therapeutics, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy

Positive Results Announces from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS® (ocrelizumab) with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Multiple Sclerosis

Halozyme Announces argenx Receives FDA Approval for VYVGART Hytrulo With ENHANZE for Subcutaneous Use in Generalized Myasthenia Gravis

Insufficient new directors

First quarter 2023 earnings released: EPS: US$0.29 (vs US$0.44 in 1Q 2022)

Halozyme Therapeutics, Inc. Reiterates Revenue Guidance for the Full Year 2023

Insufficient new directors

Investor sentiment deteriorates as stock falls 19%

Independent Director recently sold US$962k worth of stock

Full year 2022 earnings released: EPS: US$1.48 (vs US$2.86 in FY 2021)

Halozyme Therapeutics, Inc. to Report Q4, 2022 Results on Feb 21, 2023

Halozyme Therapeutics Appoints Barbara Duncan to Its Board of Directors

Halozyme Therapeutics, Inc. Provides Revenue Guidance for the Fiscal Year 2023

Independent Director recently sold US$1.7m worth of stock

CFO & Director recently sold US$269k worth of stock

Third quarter 2022 earnings released: EPS: US$0.45 (vs US$1.53 in 3Q 2021)

Halozyme Therapeutics, Inc. Reiterates Financial Guidance for the Year 2022

Halozyme Therapeutics, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Second quarter 2022 earnings released: EPS: US$0.16 (vs US$0.64 in 2Q 2021)

Halozyme Therapeutics, Inc. Revises Earnings Guidance for the Year 2022

Halozyme Therapeutics, Inc. Announces Positive Results from Phase III IMscin001 Study Evaluating Subcutaneous Formulation of Tecentriq with ENHANZE in Advanced Non-Small Cell Lung Cancer

Halozyme Therapeutics, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Investor sentiment improved over the past week

Halozyme Therapeutics, Inc. Announces Commercial Launch of TLANDO, an Oral Treatment for Testosterone Replacement Therapy

Investor sentiment improved over the past week

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) completed the acquisition of Antares Pharma, Inc. (NasdaqCM:ATRS).

Halozyme Therapeutics, Inc. Reiterates Earnings Guidance for the Year 2022

First quarter 2022 earnings released: EPS: US$0.44 (vs US$0.20 in 1Q 2021)

Halozyme Therapeutics, Inc. to Report Q1, 2022 Results on May 10, 2022

Insufficient new directors

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) entered into a definitive agreement to acquire Antares Pharma, Inc. (NasdaqCM:ATRS) for $970 million.

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) entered into a definitive agreement to acquire Antares Pharma, Inc. (NasdaqCM:ATRS) for $970 million.

Insufficient new directors

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Halozyme Therapeutics, Inc. Reiterates Earnings Guidance for the Year 2022

Halozyme Therapeutics, Inc. to Report Q4, 2021 Results on Feb 24, 2022

Halozyme Therapeutics, Inc. Announces Executive Changes

Halozyme Therapeutics, Inc. Announces Change of Chief Financial Officer

Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Year 2022

Investor sentiment improved over the past week

Halozyme Therapeutics, Inc. (NasdaqGS:HALO) announces an Equity Buyback for $750 million worth of its shares.

Independent Chairperson of the Board recently sold US$1.3m worth of stock

Third quarter 2021 earnings released: EPS US$1.53 (vs US$0.27 in 3Q 2020)

Insufficient new directors

Insufficient new directors

Independent Director recently sold US$1.4m worth of stock

Second quarter 2021 earnings released: EPS US$0.64 (vs US$0.19 in 2Q 2020)

Halozyme Therapeutics, Inc. Announces Janssen Receives European Marketing Authorizations for Darzalex® (Daratumumab) Subcutaneous Formulation for Newly Diagnosed Systemic Light-Chain Amyloidosis and Pre-Treated Multiple Myeloma

First quarter 2021 earnings released: EPS US$0.20 (vs US$0.044 loss in 1Q 2020)

Halozyme Therapeutics, Inc. Provides Earnings Guidance for the Year of 2021